Key result
Polymeric valve prostheses demonstrated superior survival compared to commercial bioprostheses in a growing calf model at 20 weeks (85.7% vs 22.2% overall survival).
Why the study?
Does a novel PCU polymeric valve prosthesis improve durability and survival compared to commercial bioprostheses in a growing calf model?
Population
Growing animal (calf) model (n=23) and in vitro testing
Comparison
Novel "biomechanical" polymeric valve prostheses… vs Commercial bioprostheses (7 mitral, 2 aortic)
Design
Preclinical
Follow-up
20 weeks (in vivo), up to 20 years (in vitro)
Authors
Loading...
May advance polymeric valves for growing patients; leaves open translation to pediatric use.
Does a novel PCU polymeric valve prosthesis improve durability and survival compared to commercial bioprostheses in a growing calf model?
Absolute Event Rate: 85.7% vs 22.2%
Novel polymeric valve prostheses demonstrated superior durability and survival compared to current bioprostheses in a growing animal model without permanent anticoagulation, suggesting potential as a future option for pediatric patients.
Sachweh et al. (2006) studied Heart valve replacement (n=23). Polymeric valve prostheses (PCU) vs. Commercial bioprostheses was evaluated on Survival at 20 weeks. Polymeric valve prostheses demonstrated superior survival compared to commercial bioprostheses in a growing calf model at 20 weeks (85.7% vs 22.2% overall survival).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: